tacrolimus + tacrolimus + Simulect + Cellcept + Corticosteroids + Ramipril + Irbesartan
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation
Trial Timeline
Aug 17, 2009 → Apr 3, 2018
NCT ID
NCT00933231About tacrolimus + tacrolimus + Simulect + Cellcept + Corticosteroids + Ramipril + Irbesartan
tacrolimus + tacrolimus + Simulect + Cellcept + Corticosteroids + Ramipril + Irbesartan is a phase 3 stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00933231. Target conditions include Kidney Transplantation.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00933231 | Phase 3 | Completed |
Competing Products
20 competing products in Kidney Transplantation